13 Treatment groups Experimental Treatment Placebo Group Part A Randomized 1:1 Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part C Sema and SC moderate dose trevo Randomized 1:2:2 Part C Sema and SC low dose trevo Randomized 1:2:2 Part C Sema and SC placebo Randomized 1:2:2 Part A Randomized 1:1 Find a Clinic Near You Who Is Running the Clinical Trial

Glucosamine Chondroitin MSM | Pain and Joint Support Supplement | Hyaluronic Acid
Product specifications CAS Registry Number 2023788-19-2 Reported purity 98.5% Form Lyophilized laboratory research material Intended use Qualified in vitro laboratory research only
PlexusDx recommends working closely with a healthcare provider throughout your treatment to monitor your response and adjust dosing cautiously